What is LAB's health score?

STANDARD BIOTOOLS INC. (LAB) has a TradeApes health score of 41 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is LAB's estimated fair value?

Based on our 5-year discounted cash flow model, STANDARD BIOTOOLS INC.'s estimated fair value is $1.12 per share, representing a 33.1% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is LAB undervalued or overvalued?

Our model currently rates LAB as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

4 free score cards remaining

STANDARD BIOTOOLS INC. (LAB)

Healthcare Undervalued low weak

$0.84

Updated: 2026-07-15

TradeApes Score

Financial Strength

25 Stressed

Operating Trend

40 Weak

Relative Value

50 Mixed

Capital Allocation

30 Weak

Risk Management

80 Strong

Est. Fair Value $1.12

DCF Upside +33.1%

Sector Rank #4781 of 12118

Key Findings

+ Low P/E — below 12×, potential value relative to earnings

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

Industry Related Stocks

AGILENT TECHNOLOGIES, INC. (A) Alamar Biosciences, Inc. (ALMR) ASTROTECH Corp (ASTC) Avantor, Inc. (AVTR) BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) BIO-RAD LABORATORIES, INC. (BIO)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.